Evolus, Inc. commercializes cash-pay medical aesthetic products for the global performance beauty market. Its portfolio centers on Jeuveau® (prabotulinumtoxinA-xvfs), known as Nuceiva® outside the United States, and injectable hyaluronic acid gel collections marketed under the Evolysse® and Estyme® brands.
Recurring Evolus news includes quarterly financial results, revenue outlooks, product and market expansion for injectable aesthetics, CE Mark certification for HA gel collections, national-account and customer engagement updates, healthcare conference participation, and equity compensation grants under Nasdaq inducement rules. Company updates also discuss operations across the United States, Canada, Europe, and Australia.
Evolus, Inc. (NASDAQ: EOLS) announced a significant investment from its partner, Daewoong Pharmaceutical Co. Ltd., amounting to $40 million through a five-year, unsecured, subordinated, 3% convertible note. The conversion price is set at $13.00, a 144% premium over the stock's closing price on July 6, 2020. This investment reflects Daewoong's long-term commitment to Evolus and confidence in its intellectual property. With this funding, Evolus anticipates a strong pro forma cash position of $125 million following the transaction.
Evolus, Inc. (NASDAQ: EOLS) reported a non-binding initial decision from the Administrative Law Judge in the US International Trade Commission case brought by Allergan and Medytox. The ruling found a violation of Section 337 of the Tariff Act, with a final determination expected by November 6, 2020. Evolus disagrees with the ruling and plans to petition for its review, arguing that the case improperly uses the USITC to resolve a dispute between two foreign competitors. Despite the ongoing legal issues, the launch and product supply of Jeuveau remain unaffected.
Evolus, Inc. (Nasdaq: EOLS) reported Q1 2020 financial results, revealing net revenues of $10.5 million, affected by a $10.2 million coupon provision. The gross margin was approximately 60%, lower than previous quarters due to increased coupon activity. The company implemented measures to conserve cash, including a 40% workforce reduction. Despite challenges from COVID-19, Jeuveau® saw a 15% increase in purchasing accounts, totaling over 4,100. Evolus projects nominal revenues for Q2 2020 but anticipates sequential improvement in U.S. net revenues for the remainder of the year.
Evolus, Inc. (NASDAQ: EOLS) will release its first quarter 2020 financial results on May 11, 2020, after U.S. market close. The company, known for its innovative aesthetic product Jeuveau®, invites investors to join a conference call at 4:30 p.m. ET on the same day. Participants can access the call via specific dial-in numbers or through a live audio webcast on Evolus' Investor Relations page. A replay will be available for a limited time post-call. Evolus aims to revolutionize the beauty industry with its customer-centric approach and advanced technology.